Invivyd is developing antibodies to transcend the limits of naturally occurring immunity and provide higher levels of protection from viral diseases, beginning with COVID-19.

We are driven to change the paradigm for combatting viral infection by delivering rapid and lasting antibody immunity to protect the general public and ensure vulnerable populations are never left behind.

In the endemic phase, SARS-CoV-2 continues to inflict an unacceptable burden on humankind. The immune response to vaccines has helped keep us alive but leaves us at continued risk. Nonetheless, SARS-CoV-2 continues to be a leading cause of death during the pandemic.

Every day, the cumulative burden of COVID-19 increases:

  • Case counts
  • Deaths
  • Long COVID-19

While natural antibody titers wane, tens of millions immunocompromised and elderly remain at unacceptably high risk.

SARS-CoV-2 will continue to evolve and may lead to further reduced vaccine effectiveness. To be safe and well, we require higher quality, more durable antibodies than our immune systems can produce in response to vaccination or infection.

There must be a better way. New tools are needed to reduce societal impact and protect vulnerable populations.

Invivyd’s technology platform is engineered to provide robust solutions to protect the vulnerable by transcending the limitations of antibodies generated by the human immune response.

Our discovery platform identifies antibodies that target parts of the virus spike protein that are under limited immune pressure, thereby increasing the probability of sustained utility. These antibodies are screened, engineered, and selected for high potency and breadth of activity across strains, as well as favorable manufacturability.

Such antibodies may be deployed prior to exposure to prevent disease, or once sick to treat disease.

Invivyd is powering the return to normal with engineered antibodies designed to match and overcome the challenges of viral evolution. To find them, we are exploring a vast universe of antibodies beyond the common human repertoire.

We have multiple next generation engineered antibodies for COVID-19 in our pipeline, several of which will be entering the clinic in the first quarter of 2023, as well as ADG20 (adintrevimab), which has demonstrated clinically meaningful results in global Phase 3 clinical trials against multiple variants of concern for the prevention and treatment of COVID-19. Commercial preparation for ADG20 is underway pending regulatory review should a susceptible variant arise. Beyond COVID-19, we have multiple antibody candidates in discovery stage for seasonal influenza.

Do you want to be part of a dynamic team in search of solutions to dynamic viral challenges?